title: Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responses.
abstract: OBJECTIVE
  To replicate the genome-wide associations of the antihypertensive effects of bisoprolol and losartan in GENRES, using the Finnish patients of LIFE study.
  
  
  METHODS
  We analyzed association of four SNPs with atenolol and three SNPs with losartan response in 927 Finnish LIFE patients (467 for atenolol and 460 for losartan).
  
  
  RESULTS
  rs2514036, a variation at a transcription start site of ACY3, was associated with blood pressure response to atenolol in men in LIFE. Response to bisoprolol was correlated to baseline plasma levels of N-acetylphenylalanine and phenylalanine (ACY3 substrate and end product, respectively) in GENRES study. NPHS1 variation rs3814995 was associated with losartan effect in LIFE.
  
  
  CONCLUSIONS
  We provide support for two pharmacogenomic markers for beta-blockers and angiotensin receptor antagonists.
authors.affiliation: Department of Medicine, University of Helsinki, Finland.|Helsinki University Hospital, Helsinki, Finland.
authors.forename: Jenni M
authors.initials: JM
authors.lastname: Rimpelä
authors.affiliation: Department of Medicine, University of Helsinki, Finland.|Helsinki University Hospital, Helsinki, Finland.
authors.forename: Kimmo K
authors.initials: KK
authors.lastname: Kontula
authors.affiliation: Minerva Foundation Institute for Medical Research, Helsinki, Finland.
authors.forename: Frej
authors.initials: F
authors.lastname: Fyhrquist
authors.affiliation: Institute for Molecular Medicine Finland, University of Helsinki, Finland.
authors.forename: Kati M
authors.initials: KM
authors.lastname: Donner
authors.affiliation: Helsinki University Hospital, Helsinki, Finland.
authors.forename: Annukka M
authors.initials: AM
authors.lastname: Tuiskula
authors.affiliation: Institute for Molecular Medicine Finland, University of Helsinki, Finland.
authors.forename: Antti-Pekka
authors.initials: AP
authors.lastname: Sarin
authors.affiliation: Metabolon, Inc., Durham, NC, USA.
authors.forename: Robert P
authors.initials: RP
authors.lastname: Mohney
authors.affiliation: Metabolon, Inc., Durham, NC, USA.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Stirdivant
authors.affiliation: Department of Medicine, University of Helsinki, Finland.|Helsinki University Hospital, Helsinki, Finland.
authors.forename: Timo P
authors.initials: TP
authors.lastname: Hiltunen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000581:Amidohydrolases / Q000235:genetics*; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects* / Q000235:genetics*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005387:Finland / Q000453:epidemiology; D014644:Genetic Variation / Q000235:genetics*; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011237:Predictive Value of Tests; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D008565:Membrane Proteins; C113267:nephrin; D000581:Amidohydrolases; C575983:aminoacylase III, rat
keywords: aminoacylase 3; atenolol; bisoprolol; genome-wide; hypertension; losartan; nephrin; pharmacogenomics